I. Pisoni

发表

Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

R. Rappuoli, S. Szu, A. Saul, 2011, Vaccine.

Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent?

I. Pisoni, P. Allaria, A. Giangrande, 1999, Journal of nephrology.

Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM197 conjugate vaccine

I. Jónsdóttir, R. Rappuoli, F. Necchi, 2020, Proceedings of the National Academy of Sciences.

Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi.

A. Saul, P. Costantino, F. Micoli, 2012, Vaccine.

Development of FAcE (Formulated Alhydrogel competitive ELISA) method for direct quantification of OAg present in Shigella sonnei GMMA-based vaccine and its optimization using Design of Experiments approach.

F. Necchi, A. Saul, O. Rossi, 2019, Journal of immunological methods.

Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi.

A. Saul, Laura B Martin, F. Micoli, 2012, Journal of infection in developing countries.

Plant pharming of a full-sized, tumour-targeting antibody using different expression strategies.

C. Marusic, A. Desiderio, E. Benvenuto, 2009, Plant biotechnology journal.

A scalable method for O-antigen purification applied to various Salmonella serovars.

C. MacLennan, A. Colucci, A. Saul, 2013, Analytical biochemistry.

Tumor vascular targeting

D. Neri, I. Pisoni, J. Mårlind, 2006 .